Next-generation PARP inhibitor shows clinical benefit in certain patients with breast cancer
Saruparib conferred clinically impactful treatment outcomes among adults with breast cancer who harbor certain genetic mutations, according to data presented at American Association for Cancer Research Annual Meeting. Researchers also reported a favorable safety profile for the investigational agent, along with a low dose reduction rate compared with certain approved [poly(ADP)-ribose polymerase